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We have constructed a hairpin ribozyme targeted to cleave a conserved sequence in the HIV-1 pol gene. The ribozyme 
was modified to include a structure-stabilizing tetraloop. In vitro studies revealed a cleavage fficiency unprecedented for 
hairpin ribozymes (kcat/K,~ = 75 min -1 /~M-1). Stable retroviral vector transduction of this ribozyme gene in T-cell lines 
resulted in long-term ribozyme xpression. As compared to control vector transduced T-cells, the pol ribozyme-transduced 
cells exhibited significant inhibition of different strains of HiV-1 virus production; this protection was greater when ribozyme 
expression was driven from an internal pol III promoter (adenovirus VA1) than when driven by a pol II promoter (the MMLV 
LTR). These results further demonstrate the potential of hairpin ribozymes a's anti-HIV gene therapy agents and suggest 
possibilities for employing combinations of independently targeted hairpin ribozymes. © 1995 Academic Press. inc. 
INTRODUCTION 
Because of the ability of ribozymes to bind to and 
cleave viral substrate RNAs (Cech et aL, 1981; Guer- 
rier-Takada etaL, 1983), these catalytic RNA molecules 
are being adapted to antiviral gene therapy, specifi- 
cally, anti-HIV gene therapy (Sarver et aL, 1990). The 
catalytic properties of ribozymes give them a potential 
advantage over antisense RNAs (Rossi et aL, 1992). 
Both hammerhead and hairpin ribozymes, which derive 
their names from their characteristic secondary struc- 
tures, are small molecules that can be readily engi- 
neered to cleave target RNA with high efficiency and 
specificity (Forster and Symons, 1987; Uhlenbeck, 
1987; Hampel et aL, 1990). Both have been shown to 
specifically recognize and cleave HIV-1 RNA tran- 
scripts and thereby inhibit HIV-1 gene expression (for 
reviews see Altman, 1993; Yu et aL, 1994a). 
The hairpin ribozyme is a 50- to 60-nt catalytic RNA 
molecule that can be designed to bind and efficiently 
cleave heterologous RNA molecules in a highly specific 
manner (Hampel etaL, 1990) as long as simple targeting 
rules are followed (Hampel eta/., 1993; Anderson et aL, 
1994). To summarize, the ribozyme recognizes 5rNNNB 
N*GUC NNNNNN . . . N3 r sequence in the target RNA 
with base-pairing occurring between the ribozyme and 
the substrate in the two sequences flanking the N*GUC 
(* denotes the cleavage site). N can be any nucleotide 
Current address: Department of Pediatrics, Miller Building 109, City 
of Hope, Duarte, CA 91010-3000. 
2To whom correspondence and reprint requests should be ad- 
dressed• 
and B can be U, C, or G, but not A. We have reported 
previously that a hairpin ribozyme targeting the 5' leader 
sequence of HIV-1 is highly effective in inhibition of viral 
gene expression and replication (Ojwang eta/., 1992; Yu 
et al., 1993; Yamada et al., 1994). When the ribozyme 
was delivered via retroviral vectors and driven by the 
vector LTR or by pol III promoters, reduction of infectious 
progeny virus was >104-fold, expression of viral proteins 
was inhibited 100-to 1000-fold, and the synthesis of viral 
DNA was reduced by 50- to 100-fold in stably transduced 
T-cell lines. Moreover, this ribozyme was highly effective 
against HIV-1 in primary cells, including peripheral blood 
lymphocytes (Leavitt et al., 1994) and monocytes/macro- 
phages derived from transduced CD34+ hematopoietic 
stem/progenitor, cells (Yu et al., 1994b). 
In this study we have identified and tested a new hair- 
pin ribozyme targeted to a highly conserved region in 
the pol gene of HIV-1. This ribozyme has a modified 
sequence in loop 3 and helix 4 to increase stability. The 
sequence recognized and cleaved is 5'CACC U*GUC 
AACAUAA3 r. In vitro studies showed high cleavage effi- 
ciency, with a koat/Km value of 75 min -1 #M -1. Human T- 
cells transduced with retroviral vectors carrying the gene 
persistently expressed the ribozyme after a long period 
of time with no apparent deleterious effects on cell prolif- 
eration. Most importantly, the "intracellularly immunized" 
cells were resistant to different strains of HIV infection. 
The identification of an additional active ribozyme tar- 
geting HIV-1 raises the possibility of developing "multitar- 
get" ribozyme vectors to increase antiviral potency and 
minimize the possibility of emergence of resistant 
va ri ants. 
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MATERIALS AND METHODS 
Design and development of the hairpin ribozyme 
The site. The HIV-1 pol-specific hairpin ribozyme was 
designed to cleave the 5'CACC U*GUC AACAUAA3' tar- 
get sequence (nt 2490-2504) in the protease region of 
the pol gene of HIV-1 (Fig. 1). Numbering is according 
to the HXB2 clone of HIV-1 (Ratner et aL, 1987). This 
sequence was identified by searching for highly con- 
served GUC containing sequences in GenBank using the 
Bioseq program (Aspinall). As shown in the alignment 
below, this target sequence is highly conserved among 
different HIV-1 strains; HIV-1 Eli, which has a single A --* 
G substitution at position 2 is the only exception (see 
boldface underlined characters) among all the published 
HIV-1 sequences. 
HXB-2 CA CCU GUC AAC ATA A 
BRU CA CCU GUC AAC ATA A 
MN CA CCU GUC AAC ATA A 
OY1 CA CCU GUC AAC ATA A 
SF2 CA CCU GUC AAC ATA A 
HAN CA CCU GUC AAC ATA A 
RF CA CCU GUC AAC ATA A 
ELI CG CCU GUC AAC ATA A 
Z2 CA CCU GUC AAC ATA A 
NDK CA CCU GTC AAC ATA A 
MAL CA CCU GTC AAC ATA A 
The ribozyme. The pol-specific hairpin ribozyme was 
designed to hybridize to the bases flanking the U*GUC 
sequence of the substrate. Hybridization forms helices 1 
and 2 of 7 and 4 bp, respectively (Fig. 2). The GUU se- 
quence found in loop 3 of the conventional hairpin ribo- 
zyme (Hampel et aL, 1990) was replaced by the tetraloop 
sequence 5'GGAC (UUCG) GUCC3' (Fig. 2; Cheong eta/., 
1990). Labeled pol-specific ribozyme and corresponding 
short substrates were produced for optimization and ki- 
netic studies by transcription with [P32]CTP from synthetic 
oligodeoxynucleotide templates containing the T7 pro- 
moter as previously described (Hampel and Tritz, 1989). 
For in vitro studies all ribozymes had an additional GGG 
vector sequence at the 5' terminus and all substrates 
had GCG at the 5' terminus to allow effective transcrip- 
tion from the T7 promoter. 
Kinetic studies 
The kinetic parameters Km and koat were determined 
using the [P32]OTP-labeled ribozyme and substrate se- 
quences shown in Fig. 2 with the additional vector se- 
quence at the 5' end of each transcript. Cleavage of the 
substrate by the ribozyme was carried out in 12 mM 
MgCI2, 2 mM spermidine, and 40 mM Tris, pH 7.5, at 
37 ° as previously described (Hampel and Tritz, 1989). 
Reaction products and substrates were separated on 
20% polyacrylamide-7 M urea gels in TBE buffer and 
counted by liquid scintillation spectrometry, Concentra- 
tions of ribozymes were from 1 to 10 nM and were fixed 
for each kinetic determination. Substrate concentrations 
ranged from 10 to 200 nM for the determination of 
initial velocities. Km and kcat were  calculated from an 
Eadie-Hoffstee plot of the data as before (Hampel and 
Tritz, 1989). 
Cloning of the Pol ribozyme gene into retroviral 
vectors 
The Pol ribozyme gene was cloned into several retrovi- 
ral vectors including those containing pol III internal pro- 
moters (Yu et aL, 1993). DNA corresponding to the Pol- 
specific ribozyme, flanked by BamHI and Mlul sites, was 
synthesized on an ABI 381A DNA synthesizer and cloned 
into BamHI/Mlul sites of the plasmid pHC which contains 
the hairpin autocatalytic assette (Altschuler et aL, 1992) 
to derive the plasmid pRPol. The retroviral vector pMM- 
6 was constructed by replacing the leader sequence ri- 
bozyme gene in pMJV (Yu etaL, 1993, 1994b)with the Pol 
ribozyme gene taken from pRPol between the restriction 
sites BamHI and Mlul, leaving the pol Ill promoter and 
terminator intact (Fig. 3A). 
Another vector was constructed by placing the anti- 
pol ribozyme under the control of the MMLV LTR (pol 
II) promoter. In anticipation of constructing multitarget 
hairpin ribozyme vectors, we developed a dicistronic ret- 
roviral vector, pLPONL, containing the neogene pre- 
ceded by the 5' nontranslated region (5'NTR) of poliovi- 
rus (indicated as "PC" in Fig. 3A). Previous work showed 
that this 5'NTR allows internal initiatiOn of translation to 
occur in mammalian cells (Peltetier and Sonenberg, 
1988). pMY-1 was constructed with the anti-pol ribozyme 
gene including an autocatalytic cassette (Altschuler et 
a/., 1992; Ojwang et aL, 1992; also see construct pMJF- 
1 in Yu et al., 1993) inserted downstream of the 5'LTR of 
the retroviral vector, pLPONL, at the Hindlll site (Fig. 3A). 
Stable cell lines and ribozyme expression 
The human T-cell lines, Jurkat and Molt 4 clone 8 were 
stably transduced with retroviral vectors and established 
as previously described (Yamada eta/., 1994). Briefly, the 
retroviral vector plasmids were first transfected into the 
amphotropic retroviral packaging cell line PA317 by the 
Ca 2-- PC4 method. Virus supernatant was harvested 2 
days after transfection and used to transduce human T- 
ceil lines. Neoresistant (neo r) cells were then established 
by G418 selection (400 #g/ml). Total RNA was extracted 
from the stable cell lines by the acid guanidinium thiocya- 
nate-phenoi/chloroform extraction method (Chomczynski 
and Sacchi, 1987). One microgram of the total RNA was 
used as the template for reverse transcription. RT-PCR 
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FIG. 1. The location of the target and the sequence cleaved inthe pol gene of HIV-1. Numbering is according to the HXB2 clone of HIV-1 (Ratner 
etaL 1987). Shown below is cleavage of the HIV-1 pol substrate by HIV-1 pc] ribozyme. In this case, the pol specific hairpin ribozyme was 0.04 
ffM and the pol substrate was 0.2 tiM, incubated at 37 ° for 20 min and electrophoresed in a 20% polyacrylamide gel. Extent of cleavage was 62%. 
was carried out with a 5'-end Pol ribozyme-specific 
primer, Rib P (18 mer, 5'-q-I-A TCT TAG AAG GTG ACC- 
3'), and the 3'-end common hairpin ribozyme primer Rib 
2 (Yamada et al., 1994), using conditions described pre- 
viously (Yamada et al., 1994). After PCR with and without 
RT, 10 #1 of each amplified product was subjected to 
electrophoresis on a 3% low melting agarose gel, and 
Southern blot analysis was performed with another 32p_ 
end-labeled Pol ribozyme-specific probe, Rib T (24 mer, 
5'-AGA GAA ACA CAC GGA CTT CGG TCC-3'). 
HIV-1 virus chal lenge 
HIV-1 HXB2 virus stocks were grown in acutely in- 
fected Molt4/8 T-cells. The infectious titer (TCIDso) was 
determined using the MT-2 cell line by the standard 
method of limiting dilution. Jurkat and Molt 4/8 cells sta- 
bly expressing the Pol ribozymes and LNL6-transduced 
control cells were synchronously passaged for 2 weeks 
prior to challenge to ensure that all cell lines were chal- 
lenged under the same growth conditions. Cells were 
infected at different m.o.i.s of 0.01 and 0.001. The cells 
were washed twice with RPMI 1640 medium after virus- 
adsorption for 4 -12  hr and resuspended in RPM] 1640 
supplemented with 10% FBS at a concentration of 10 ° 
cells/ml. During the cell culturing period, small aliquots 
of the culture fluid were collected every 2 days, and the 
level of HIV-1 p24 antigen was determined by HIV-1 anti- 
gen capture ELISA test (Coulter). 
RESULTS 
In vitro kinetics of ribozyme cleavage 
The hairpin ribozyme used here (Fig. 2) has been modi- 
fied from the original hairpin motif to extend Helix 4 and 
replace loop 3 with the common RNA tetraloop sequence 
5'GGAC (UUCG) GUCC3' (Anderson et al., 1994). The 
length of helix 1 was optimized by varying its length and 
comparing cleavage rates (data not shown). It was found 
that optimal cleavage (Fig. 1) occurred when helix 1 was 
7 bp as shown in Fig. 2. Helix 2 is fixed at 4 bp according 
to the target selection rules for the hairpin ribozyme. 
In vitro characterization of this ribozyme showed high 
cleavage efficiency. For the kinetic analysis, the ribozyme 
concentration was limiting, the substrate was present in 
excess, and reaction times were such that reaction rates 
were close to linear. The catalytic efficiency was kcat/Km 
= 75 min -1 #M -1. The individual kinetic parameters were 
measured to be, Km= 6.7 nM and koa t = 0.5 min -~ (Table 
1). This ribozyme has the highest catalytic efficiency re- 
ported yet for a hairpin ribozyme. 
Long term ribozyme expression in T-cells 
Expression of the ribozyme gene in the stably trans- 
duced Human Jurkat cell lines was examined by PCR 
combined with RT, using specific Pol ribozyme primers. 
Figure 3B shows the results of ribozyme expression in 
Jurkat cells 5 months (approximately 20 passages) after 
transduction with the retroviral vectors carrying the Pol 
Site of cleavage 
Catalytic RNA p ~]  [ Loo 4 Substrate RNA 
(<2 GUCCGUG CUGG I cacc  aacauaa 3' 
I <  . . . . . . . . . . . . . . . . . . . . . .  
~,  U CAGGCAC ACAAAG AGACC A GUGG AAGAUUGUAUUJ 5' 
Tetraloop Helix 4 Loop 2 Helix 3 Helix 2 Loop 1 Helix 1 
FIG. 2. The HJV-1 pol specific hairpin ribozyme. 
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TABLE 1 
COMPARISON OF CATALYTIC EFFICIENCY OF HAIRPIN RIBOZYMES 
K m kca t Catalytic 
Target (riM) (min -~) efficiency ~ 
Native 30 2.1 70 
UGACA*GUCCUGUUU 
HIV-1 pol/tetraloop 6.7 0.5 75 
2490-2504 
CACCU*GUCAAOAUAA 
HIV-1 Pol 42 0.2 5 
2490-2504 
OACCU*G UCAACAUAA 
HIV-1 5' leader 100 1.6 16 
561-576 
UGCCC*GUCUGUUGUGU 
Note. Catalytic parameters of the pol ribozyme, both with or without 
the tetraloop modification, were determined as described under materi- 
als and methods. These were compared to those of the native se- 
quence (Hampel and Tritz, 1989) and the HIV-1 5' leader ribozyme 
(Ojwang et at., 1992). The target sequence ofeach ribozyme is hown. 
a kcat /K  m (min 1 #M-l). 
ribozyme. A 60-bp RT-PCR amplified product was de- 
tected in both MY-1 and MM6 retroviral vector-trans- 
duced Jurkat cells (Fig. 3B, lanes 2 and 8, respectively). 
This Pol ribozyme-specific RNA product was, however, 
not detected in Jurkat cells transduced by control vectors, 
which include the vector alone (LNL6) and a HIV-1 leader 
sequence ribozyme vector (MJT; Yu et  aL, 1994b). Further- 
more, the product was derived from RNA, not DNA, since 
no amplified product was observed in the absence of RT 
in the PCR process (lanes 1, 3, 5, and 7). There was no 
deleterious effect of long term expression of the ribozyme 
on cell proliferation as evaluated and compared by cell 
growth and cell viability (data not shown). 
such as secondary structural and cellular compartmental- 
ization. As a positive control for the challenge experi- 
ments, we included Jurkat and Molt 4/8 cells transduced 
by MJT, which expresses the HIV-1 leader sequence ribo- 
zyme as previously published (Yamada et  al., 1994). As 
shown in Fig. 4A, a greater reduction in p24 expression 
was observed in cells transduced by MM6 than those 
transduced by MJT. Similar results in the gradation of 
antiviral efficacy (i.e., MM6 > MJT > MY -1 > LNL6) 
was observed when transduced Molt 4/8 cells were chal- 
lenged with virus (Fig. 4B). To investigate the ability of 
JMM-6 to resist the replication of different HIV-1 strain and 
the ability of longer term resistance, we further challenged 
JLNL6 and JMM6 with HIV-1 MN strain (Fig. 5). In this 
experiment, expression of p24 in MN-infected JMM6 cells 
was reduced to background levels up to 5 weeks postin- 
fection. The reduction of p24 level in JLNL6 cells after 4 
weeks was caOsed by extensive cell death due to the 
CPE of the HIV-infected cells as we and others frequently 
observed for long term-infected cultures. 
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Inhibition of HIV-1 replication by the Pol ribozyme 
We investigated the HIV-1 inhibitory effects of the Pol 
ribozyme in Jurkat and Molt 4/8 cells transduced with 
MM6 and MY-1 (see Materials and Methods). LNL6 vec- 
tor-transduced Jurkat cells were used as a negative con- 
trol. As shown in Fig. 4, the expression of p24 antigen in 
the culture supernatant of cells infected by the H IV-1 HXB2 
strain was reduced 85% in JMY-1 and 99% in JMM6 up to 
Day 7 in comparison with the control (JLNL6). Expression 
of p24 in HXB2-infected JMM6 cells was reduced to back- 
ground levels up to Day 12 postinfection, while HIV-1 P24 
expression broke through in HXB2-infected JMY-1 cells. 
The relatively higher efficiency of virus inhibition of the 
MM-6 ribozyme vector may be attributable to the higher 
level of expression and/or greater stability of the pol Ill- 
driven transcript (see Fig. 2B) as well as to other factors 
60 bp 
- -I- + + + RT 
JMY-1 JMJT JLNL6 JMM6 
FIG. 3. (A) Schematic representation of the retroviral vector con- 
structs. For pMM-6, two restriction e zyme sites are indicated which 
were used to replace the leader sequence ribozyme (Yu et aL, 1994b) 
by the pol ribozyme. VA1, adenevirus VA1 promoter. (B) Expression of 
the ribozyme in stable cell lines. The expression of ribozyme RNA 
was examined by PCR combined with reverse transcription. -RT, PCR 
without reverse transcriptase. Each Jurkat cell line used is indicated 
under the corresponding lanes. The size of the amplified product is 
marked. 
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FIG. 4. Inhibition of HIV-1 HXB2 replication by the pol ribozyme. Jurkat (A) and Molt4/8 (B) cell lines stably transduced with LNL-6 (O), MY-1 (D), 
MJT (A), and MM-6 (©) were challenged with HXB2 at m.o.i, of 0.01. Virus production was monitored by p24 antigen level. 
DISCUSSION 
In our previous preclinical studies, we demonstrated 
the potential of a hairpin ribozyme for anti-HIV gene ther- 
apy (Yu eta/,, 1993; Yamada eta/,, 1994). Our subsequent 
efforts have been directed at increasing the catalytic effi- 
ciency of ribozymes in vivo, as well as exploring the use 
of alternative targets and developing multitarget ribo- 
zyme vectors. We describe here the designing and opti- 
mization by in vitro cleavage of a modified hairpin ribo- 
zyme which showed unprecedented enzyme kinetics in 
vitro. This ribozyme targets a conserved region in the pol 
gene of HIV-1 (Fig. 1) and confers resistance to virus 
infection when stably transduced into a human T-cell 
line. The modification was that the standard GUU loop 3 
sequence of the hairpin ribozyme (Hampel et aL, 1990; 
Ojwang et aL, 1992) was replaced by a 12-nt tetraloop 
sequence, 5'GGAC (UUCG) GUCC3', commonly found in 
cellular RNA structures. The resulting tetraloop ribozyme 
has a 7-bp helix 4 (only 3 bp in the conventional hairpin 
ribozyme) and a new UUCG sequence in loop 3. The 
tetraloop forms a very stable structure; only one nucleo- 
tide in the loop is exposed (Cheong et aL, 1990). There- 
fore, the new structure was added to simultaneously en- 
hance stability of the ribozyme and decrease the size of 
the exposed loop 3. 
The target for this ribozyme was a highly conserved 
region in the pol gene of HIV-1. In comparing sequences 
in this region from geographically diverse isolates of HIV- 
1, only one variant, ELI, was found to contain a mutation, 
a single base change A -~ G in position 2492. There is 
a mismatch for the leader sequence ribozyme in MN 
strain (see Yu et aL, 1993); however, the combination of 
these two ribozymes will cover the entire HIV-1 spectrum. 
The catalytic efficiency, kcat/Km, of 75 #M- lmin -1 for the 
pol-specific hairpin ribozyme is the highest we have ob- 
served for any hairpin ribozyme including the native ribo- 
zyme (Table 1). Its catalytic efficiency is 15 times that of 
the pol ribozyme without the tetraloop modification and 
4.7 times that of the 5' leader ribozyme (Ojwang et aL, 
1992), which we previously showed to be highly efficient 
in reducing expression of viral proteins and inhibition of 
proviral DNA synthesis (Yu et aL, 1993, 1994b; Yamada 
et aL, 1994; Leavitt et al., 1994). The persistent ribozyme 
expression in a human T-cell line (Fig. 3B) indicates that 
long-term stable expression is possible. As observed 
previously, we found that protection of human T-cells 
from different strains of HIV-1 infection was more exten- 
sive when the ribozyme gene was expressed from a pol 
Ill promoter as opposed to a pol II promoter (Fig. 4; Yu 
et aL, 1993; Yamada et al., 1994). However, the pMY-1 
was not used here for direct comparison of promoter 
strength; rather, it was designed as a first step towards 
the construction of multitarget ribozyme vectors and test- 
ing of the internal ribosome entry site (Fig. 3B; "PC"). The 
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FIG. 5. Long term inhibition of HIV-1 MN replication by tlqe pol ribo- 
zyme. Jurkat cell tines stably transduced with LNL-6 (1~1) and MM-6  
(A) were chal lenged with MN at m.o.i, of 0,001. Virus production was 
monitored by p24 antigen level. 
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successful establishment of the stable cell lines, JMY-1 
and MMY-1, suggests that the neoprotein can be synthe- 
sized by internal initiation of translation. 
The immediate future experiments include expression 
of two ribozymes (leader sequence and pol) simulta- 
neously in the hope of delivering a "one-two punch" 
against HIV-1. This may be an especially promising ap- 
proach since the two ribozymes act entirely indepen- 
dently and have different kinetic parameters. The pol 
ribozyme has a high substrate affinity with low substrate 
concentration requirement while the leader, sequence ri- 
bozyme requires higher substrate concentration, but has 
faster cleavage rate (Table 1). Therefore, the former could 
serve as the "house cleaner" when the viral targets are 
lowered by the active cleavage of the leader sequence 
ribozyme. We have already developed several different 
multitarget ribozyme retroviral vectors, and functional 
tests are in progress. 
The potential for mutational escape is a potential draw- 
back to any antiviral strategy. HIV-1 has a particularly 
high mutation rate, a property already well documented 
to result in, for example, AZT resistant viruses. We seek 
to diminish the likelihood of mutational escape by tar- 
geting highly conserved regions and by combining sev- 
eral targets or approaches. We have, in this study, char- 
acterized a second functional hairpin ribozyme that has 
been modified for increased activity and which recog- 
nizes a different target sequence from that previously 
described. A repertoire of independently targeted hairpin 
ribozymes may allow a combination strategy able to effi- 
ciently block virus replication and emergence of resistant 
mutants. 
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